* Portfolio
* About
* Team
* News
* Careers
* Contact
* LP Login
Early growth equity for rapidly-scaling B2B software and healthcare companies
Partnering with exceptional teams since 1983
CEO SPOTLIGHTS
We partner with strong CEOs of high-growth businesses, and together we scale.
Delivering managed detection and response (MDR) across the enterprise.
READ MORE
Above all, I genuinely believe that NMP cares about the team and the company’s success. It’s not just about the return we generate. I can’t overstate how much that trust matters.
Brian Beyer
CEO and co-founder of Red Canary
Offering best in class infusion therapy in under-served markets.
READ MORE
If I started another company, NMP is the first investor I would call.
Gus De Avillez
CEO of Medix Infusion
Solving complex pricing challenges with next-generation revenue management software.
READ MORE
NMP has added tremendous value beyond capital. They helped us put together a board of operators with $1B+ exits, guided us on our transition from services to SaaS, and supported us through the pandemic.
Dax Cross
Co-founder of Revenue Analytics
Delivering comprehensive care at home.
READ MORE
A lot of firms focused on the “buzz” while Noro-Moseley was focused on developing a sustainable economic model and a scalable, successful business.
Travis Messina
Former CEO of Contessa
Our Exits
Our exits represent over $ 4 billion in aggregate enterprise value since 2015
acquired by
acquired by
acquired by
acquired by
acquired by
acquired by
acquired by
acquired by
acquired by
acquired by
NMP Investment Criteria
We are actively investing in businesses that meet these key criteria
* Year-over-year growth
50%+
* Compelling unit economics
* Target revenue run rate
$ 2M-20M
* nmp target investment
$ 5-20m
* SIGNIFICANT OPPORTUNITY FOR MARKET DISRUPTION
* Minimal prior funding
< $ 20M
NMP Portfolio News
view all news
* April 16, 2025
Liminal Raises $ 8.5M Series A to Build the Intelligence Platform for Complex Markets and Regulated Industries
* December 12, 2024
Red Canary Delivers Record Q3, Maintaining Customer-Validated 99% Threat Accuracy at Scale
* August 13, 2024
Upward Health Ranks No. 6 on the 2024 Inc. 5000
* August 2, 2024
SPS Commerce Acquires SupplyPike
* July 25, 2024
QuVa Pharma Completes Acquisition of LogicStream Health
* July 17, 2024
AutoScheduler.ai Secures $ 6.5M Funding from Noro-Moseley Partners
view all news
* Portfolio
* About
* Team
* News
* Careers
* Contact
* LP Login
* ©2024 Noro-Moseley Partners. All Rights Reserved.
*
* The Medici Building
3284 Northside Parkway, NW
Suite 525
Atlanta, Georgia 30327-2337
Directions | Direct: 404.233.1966 |
* Portfolio
* About
* Team
* News
* Careers
* Contact
* LP Login
Early growth equity for rapidly-scaling B2B software and healthcare companies
Partnering with exceptional teams since 1983
CEO SPOTLIGHTS
We partner with strong CEOs of high-growth businesses, and together we scale.
Delivering managed detection and response (MDR) across the enterprise.
READ MORE
Above all, I genuinely believe that NMP cares about the team and the company’s success. It’s not just about the return we generate. I can’t overstate how much that trust matters.
Brian Beyer
CEO and co-founder of Red Canary
Offering best in class infusion therapy in under-served markets.
READ MORE
If I started another company, NMP is the first investor I would call.
Gus De Avillez
CEO of Medix Infusion
Solving complex pricing challenges with next-generation revenue management software.
READ MORE
NMP has added tremendous value beyond capital. They helped us put together a board of operators with $1B+ exits, guided us on our transition from services to SaaS, and supported us through the pandemic.
Dax Cross
Co-founder of Revenue Analytics
Delivering comprehensive care at home.
READ MORE
A lot of firms focused on the “buzz” while Noro-Moseley was focused on developing a sustainable economic model and a scalable, successful business.
Travis Messina
Former CEO of Contessa
Our Exits
Our exits represent over $ 4 billion in aggregate enterprise value since 2015
acquired by
acquired by
acquired by
acquired by
acquired by
acquired by
acquired by
acquired by
acquired by
acquired by
NMP Investment Criteria
We are actively investing in businesses that meet these key criteria
* Year-over-year growth
50%+
* Compelling unit economics
* Target revenue run rate
$ 2M-20M
* nmp target investment
$ 5-20m
* SIGNIFICANT OPPORTUNITY FOR MARKET DISRUPTION
* Minimal prior funding
< $ 20M
NMP Portfolio News
view all news
* April 24, 2025
A Tariff Crisis Is A Terrible Thing To Waste: Pricing And Profits
* April 16, 2025
Liminal Raises $ 8.5M Series A to Build the Intelligence Platform for Complex Markets and Regulated Industries
* December 12, 2024
Red Canary Delivers Record Q3, Maintaining Customer-Validated 99% Threat Accuracy at Scale
* August 13, 2024
Upward Health Ranks No. 6 on the 2024 Inc. 5000
* August 2, 2024
SPS Commerce Acquires SupplyPike
* July 25, 2024
QuVa Pharma Completes Acquisition of LogicStream Health
view all news
* Portfolio
* About
* Team
* News
* Careers
* Contact
* LP Login
* ©2024 Noro-Moseley Partners. All Rights Reserved.
*
* The Medici Building
3284 Northside Parkway, NW
Suite 525
Atlanta, Georgia 30327-2337
Directions | Direct: 404.233.1966 |
|